


## AMENDMENTS TO THE CLAIMS:

### Listing of Claims:

Claim 1 (currently amended): A combination for simultaneous, separate or sequential use for the treatment of patients with chronic lymphocytic leukemia which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide and uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl-benzamide having the following formula



in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt.

Claim 2 (original): The combination according to claim 1 which is a fixed combined pharmaceutical composition.

Claim 3 (previously presented): The combination according to claim 1 wherein (a) and (b) are present in synergistically effective amounts.

Claim 4 (previously presented): The combination according to claim 1 wherein the nitrogen mustard analogue is chlorambucil.

Claim 5 (cancelled)

Claim 6 (previously presented): The combination according to claim 1 used in a preparation of a medicament for the treatment of chronic lymphocytic leukemia.

Claim 7 (currently amended): The combination according to claim 4-5 wherein leukemia is a chlorambucil-resistant chronic lymphocytic leukemia.

Claim 8 (previously presented): A method of treating a warm-blooded animal having chronic lymphocytic leukemia comprising administering to said animal a combination according to claim 1 in a quantity which is jointly therapeutically effective against said disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 9 (original): The method according to claim 8 wherein (a) chlorambucil is administered at a dose of 0.2 to 0.8 mg/kg of body weight/day and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide is administered at a dose of 50 mg to 800 mg per day.

Claim 10 (previously presented): A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against chronic lymphocytic leukemia of the combination according to claim 1 and at least one pharmaceutically acceptable carrier.

Claim 11 (original): A commercial package comprising a pharmaceutical composition according to claim 10 together with instructions for simultaneous, separate or sequential use thereof in the treatment of chronic lymphocytic leukemia.

Claim 12 (previously presented): A method of treating a warm-blooded animal having chronic lymphocytic leukemia comprising 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide in free form or in the form of a pharmaceutically acceptable salt for the manufacture of a medicament in combination with a nitrogen mustard analog selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide and uracil mustard.

Claim 13 (previously presented): The method according to claim 12 wherein the nitrogen mustard analogue is chlorambucil.